| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1169 | 2021 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 936 | 2022 |
| Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal … A Singanayagam, S Hakki, J Dunning, KJ Madon, MA Crone, A Koycheva, ... The lancet infectious diseases 22 (2), 183-195, 2022 | 879 | 2022 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 802 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 715 | 2021 |
| Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season A Meijer, A Lackenby, O Hungnes, B Lina, S van Der Werf, B Schweiger, ... Emerging infectious diseases 15 (4), 552, 2009 | 525 | 2009 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 476 | 2021 |
| Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe A Lackenby, O Hungnes, SG Dudman, A Meijer, WJ Paget, AJ Hay, ... Eurosurveillance 13 (5), 3-4, 2008 | 421 | 2008 |
| Late Ebola virus relapse causing meningoencephalitis: a case report M Jacobs, A Rodger, DJ Bell, S Bhagani, I Cropley, A Filipe, RJ Gifford, ... The Lancet 388 (10043), 498-503, 2016 | 389 | 2016 |
| Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 365 | 2021 |
| The mechanism of resistance to favipiravir in influenza DH Goldhill, AJW Te Velthuis, RA Fletcher, P Langat, M Zambon, ... Proceedings of the National Academy of Sciences 115 (45), 11613-11618, 2018 | 337 | 2018 |
| Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08 SH Hauge, S Dudman, K Borgen, A Lackenby, O Hungnes Emerging infectious diseases 15 (2), 155, 2009 | 298 | 2009 |
| Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives AC Hurt, T Chotpitayasunondh, NJ Cox, R Daniels, AM Fry, LV Gubareva, ... The Lancet infectious diseases 12 (3), 240-248, 2012 | 251 | 2012 |
| Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children I Stephenson, J Democratis, A Lackenby, T McNally, J Smith, M Pareek, ... Clinical Infectious Diseases 48 (4), 389-396, 2009 | 225 | 2009 |
| Neuraminidase receptor binding variants of human influenza A (H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? YP Lin, V Gregory, P Collins, J Kloess, S Wharton, N Cattle, A Lackenby, ... Journal of virology 84 (13), 6769-6781, 2010 | 223 | 2010 |
| Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014 E Takashita, A Meijer, A Lackenby, L Gubareva, H Rebelo-de-Andrade, ... Antiviral research 117, 27-38, 2015 | 185 | 2015 |
| The potential impact of neuraminidase inhibitor resistant influenza A Lackenby, CI Thompson, J Democratis Current opinion in infectious diseases 21 (6), 626-638, 2008 | 178 | 2008 |
| Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017 A Lackenby, TG Besselaar, RS Daniels, A Fry, V Gregory, LV Gubareva, ... Antiviral research 157, 38-46, 2018 | 149 | 2018 |
| Variation in the ability of human influenza A viruses to induce and inhibit the IFN-β pathway A Hayman, S Comely, A Lackenby, S Murphy, J McCauley, S Goodbourn, ... Virology 347 (1), 52-64, 2006 | 146 | 2006 |
| Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015 AC Hurt, TG Besselaar, RS Daniels, B Ermetal, A Fry, L Gubareva, ... Antiviral research 132, 178-185, 2016 | 141 | 2016 |
Professor Maria ZambonPublic Health Englandبريد إلكتروني تم التحقق منه على phe.gov.uk
